CVS Health Corporation (NYSE:CVS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025.
A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products.
CVS Health Corporation (NYSE:CVS)’s retail pharmacy business may be widely recognized, but it represents just a small portion of its broader business. The company also runs a top-tier pharmacy benefits management division and owns Aetna, a major player in the health insurance space.
Although CVS Health Corporation (NYSE:CVS)’s stock took a significant hit last year, it has rebounded this year. The stock has surged by over 43% since the start of 2025. The company also reported strong earnings in the first quarter of 2025, with revenues coming in at $94.6 billion. The revenue showed a 7% growth from the same period last year and also beat analysts’ estimates by $1.22 billion.
CVS Health Corporation (NYSE:CVS) also posted a solid cash position with an operating cash flow of $4.6 billion. The company increased its operating cash flow forecast from around $6.5 billion to roughly $7.0 billion. This cash position has enabled the company to pay uninterrupted dividends to shareholders since 1997. Currently, it offers a quarterly dividend of $0.665 per share and has a dividend yield of 4.20%, as of July 17.
While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Best Industrial Dividend Stocks to Buy Right Now and 10 Best Passive Income Stocks to Buy Now.
Disclosure: None.
